Healthcare
Scholar Rock Holding Corporation(SRRK)
Live Price
Offline$47.33
+0.81% today
1Y Change
+42.22%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $5.33B
- Revenue Growth
- 0.0%
- EPS Growth
- -33.2%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Scholar Rock Holding Corporation (SRRK) is a Healthcare stock with a market cap of $5.33B and listed on NASDAQ. The stock last traded around $47.33 and up 42.2% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -33.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -33.2%, free cash flow -49.5% with operating margin 0.0% and ROIC -108.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SRRK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -33.2%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.7% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +2.2% | -3.6% | -10.9% |
2026 Mar 3, 2026 | +0.3% | +7.0% | +1.1% | +10.9% |
2025 Nov 14, 2025 | -7.8% | -2.5% | +7.5% | +20.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SRRK
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SRRK Max Drawdown
-34.86%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SRRK and SPY.
Company Overview
Scholar Rock Holding Corporation
NASDAQ Global Select
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
- Leadership
- David L. Hallal
- IPO Date
- May 25, 2018
- Employees
- 128
- Street Address
- 301 Binney Street
- Mailing
- Cambridge, MA, 02142
- Region
- Cambridge, MA, US
- Reporting Currency
- USD
- Investor Line
- 857 259 3860
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 21.7
Growth
- Revenue
- 0.0%
- EPS
- -33.2%
- Free Cash Flow
- -49.5%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -145.9%
- ROIC
- -108.5%
Balance Sheet
- Debt/Equity
- 0.44
- Current Ratio
- 6.95
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.